Introduction to Immunomedics Inc.

Immunomedics Inc., headquartered in Morris Plains, New Jersey, stands as a premier biotechnology company dedicated to the development of monoclonal antibody-based therapies for the treatment of cancer and other serious diseases. With a rich history spanning over four decades, the company has earned global recognition for its pioneering work in antibody-drug conjugates (ADCs), radioimmunotherapy, and bispecific antibodies. Immunomedics Inc. operates at the forefront of precision oncology, leveraging its proprietary DOCK-AND-LOCK™ technology platform to create highly targeted therapeutic agents that minimize off-target toxicity while maximizing efficacy. The company’s portfolio includes both approved products—such as TRODELVY® (sacituzumab govitecan-hziy), an ADC for metastatic triple-negative breast cancer and metastatic urothelial cancer—and a robust pipeline of investigational candidates targeting solid tumors and hematologic malignancies. Immunomedics Inc. employs over 1,200 professionals across research, clinical development, manufacturing, and commercial operations, with additional facilities in Europe and Asia. Its market reputation as a leader in the Healthcare sector is underscored by numerous awards, including recognition from FiercePharma and BioCentury, and a track record of successful regulatory approvals. The company’s collaborative network spans academic institutions, contract research organizations, and global pharmaceutical partners, making it a trusted name among oncologists, researchers, and patients alike.

Immunomedics Inc.’s role within the biotechnology industry is transformative: it bridges the gap between innovative lab discoveries and life-saving medicines. The company’s integrated approach—from target identification through late-stage clinical trials—has led to breakthrough therapies that improve survival outcomes for patients with limited treatment options. Organizations ranging from top-tier cancer centers to government health agencies rely on Immunomedics Inc.’s expertise in antibody engineering and drug development. Its state-of-the-art manufacturing facility in Morris Plains complies with current Good Manufacturing Practices (cGMP) and supplies clinical and commercial products globally. As a beacon of scientific excellence, Immunomedics Inc. continues to attract top talent and investment, solidifying its position as a cornerstone of the biopharmaceutical landscape.

Company History and Business Evolution

Immunomedics Inc. was founded in 1982 by Dr. David M. Goldenberg, a renowned physician-scientist, with the vision of harnessing monoclonal antibodies for cancer diagnosis and therapy. Initially focused on developing radioimmunodetection and radioimmunotherapy agents, the company quickly established itself as a pioneer in the field. The early years were marked by the development of CEA-Scan® (arcitumomab), a diagnostic imaging agent for colorectal cancer that received FDA approval in 1996. This milestone validated Immunomedics Inc.’s technology platform and provided a revenue stream to fund further research.

Building on its early success, the company expanded into therapeutic applications, leveraging its proprietary humanized monoclonal antibodies. In the 2000s, Immunomedics Inc. advanced several candidates into clinical trials, including epratuzumab for autoimmune diseases and veltuzumab for non-Hodgkin lymphoma. However, the company’s true breakthrough came with the development of sacituzumab govitecan, an ADC targeting Trop-2. After a series of strategic pivots and financing rounds, the drug was approved by the FDA in 2020 as TRODELVY® for metastatic triple-negative breast cancer—a landmark achievement that transformed the company’s trajectory. The subsequent approval for metastatic urothelial cancer in 2021 further cemented TRODELVY® as a blockbuster therapy.

Immunomedics Inc.’s evolution has been characterized by strategic acquisitions and partnerships. In 2017, the company acquired the rights to TRODELVY® from Seattle Genetics (now Seagen) and licensed its technology to other firms, generating non-dilutive capital. The company also expanded its pipeline through collaborations with academic centers such as Memorial Sloan Kettering Cancer Center and Dana-Farber Cancer Institute. In 2020, Immunomedics Inc. was acquired by Gilead Sciences for $21 billion, a move that validated its technology and provided resources for global commercialization. Post-acquisition, Immunomedics Inc. continues to operate as a distinct subsidiary, retaining its brand identity and research culture while benefiting from Gilead’s infrastructure. The company’s journey from a small diagnostics firm to a multibillion-dollar oncology powerhouse exemplifies resilience, innovation, and strategic foresight.

Immunomedics Inc. at a Glance

• Headquarters: Morris Plains, New Jersey, USA
• Founded: 1982
• Founder: Dr. David M. Goldenberg
• Current CEO (post-acquisition): Dr. Michael Pehl (as of 2023)
• Parent Company: Gilead Sciences (since 2020)
• Employees: Approximately 1,200
• Revenue: $1.5 billion (2023, primarily from TRODELVY® sales)
• Key Product: TRODELVY® (sacituzumab govitecan-hziy)
• Technology Platforms: DOCK-AND-LOCK™, Humanized Antibodies, ADC, Radioimmunotherapy
• Therapeutic Areas: Oncology (breast, urothelial, lung, colorectal, etc.)
• Stage: Commercial-stage with robust pipeline
• Manufacturing: cGMP facility in Morris Plains, NJ
• Global Presence: Offices in Europe and Japan
• Stock (pre-acquisition): Nasdaq: IMMU (now delisted)
• Awards: FiercePharma Top Innovator, BioCentury Best of Biotech
• Clinical Trials: Over 20 ongoing studies
• Patents: 500+ granted worldwide
• Regulatory Approvals: FDA (2 indications), EMA (conditional approval)
• Key Partnerships: Gilead Sciences, Merck KGaA
• Corporate Culture: Innovation-driven, patient-centric, collaborative

Mission, Vision, and Core Corporate Values

Immunomedics Inc.’s mission is to “pioneer therapies that transform the lives of patients with cancer by leveraging our expertise in antibody engineering and targeted delivery.” This mission reflects the company’s unwavering commitment to addressing unmet medical needs through scientific rigor. The vision extends beyond treating cancer to “a world where cancer is a manageable, chronic disease or curable—thanks to precision medicines that minimize side effects.” To realize this vision, Immunomedics Inc. operates on a foundation of core values: Innovation, Integrity, Collaboration, Patient-Centricity, and Excellence. Innovation drives every research program, from novel ADC designs to combination regimens. Integrity ensures transparency in clinical data and regulatory interactions. Collaboration fosters partnerships with academia, patient advocacy groups, and healthcare providers. Patient-centricity keeps the focus on improving quality of life and survival. Excellence permeates manufacturing, compliance, and employee development. These values are embedded in daily operations, performance reviews, and strategic decisions, creating a cohesive culture that attracts world-class talent.

The company’s mission and vision are operationalized through specific initiatives: investing in early-stage research, accelerating clinical timelines, expanding access to underserved populations, and advocating for precision oncology policies. Immunomedics Inc. also publishes its environmental, social, and governance (ESG) commitments, including reducing carbon footprint and promoting diversity in clinical trials. By aligning business goals with societal impact, the company reinforces its reputation as a responsible corporate citizen.

Business Strategy and Future Roadmap

Immunomedics Inc.’s business strategy is centered on maximizing the value of TRODELVY® while expanding its pipeline through innovation and partnerships. The company pursues label expansions for TRODELVY® into additional tumor types—such as non-small cell lung cancer, colorectal cancer, and gastric cancer—via robust clinical trials. Simultaneously, it develops next-generation ADCs using its proprietary DOCK-AND-LOCK™ platform to target novel antigens with improved therapeutic indices. The future roadmap includes combinations with immuno-oncology agents (e.g., checkpoint inhibitors) to overcome resistance mechanisms and enhance response rates. Immunomedics Inc. also invests in bispecific antibodies and radioimmunotherapy, aiming to create a diverse portfolio that addresses both solid and liquid tumors.

Operationally, the company focuses on manufacturing efficiency and global commercialization. The Morris Plains facility is being upgraded to increase production capacity, while partnerships with Gilead’s global commercial network ensure broad market access. Digital health technologies, such as patient support apps and real-world evidence platforms, are being integrated to improve adherence and outcomes. Financially, Immunomedics Inc. aims to maintain a strong balance sheet through revenue from TRODELVY® and disciplined R&D spending. The long-term vision is to become a top-tier oncology company with a multi-product portfolio, achieving annual revenues exceeding $5 billion by 2030.

Products, Technologies, and Services

Immunomedics Inc.’s primary product is TRODELVY® (sacituzumab govitecan-hziy), an ADC comprising a humanized anti-Trop-2 antibody conjugated to the topoisomerase I inhibitor SN-38 via a hydrolyzable linker. Approved for metastatic triple-negative breast cancer (mTNBC) and metastatic urothelial cancer, TRODELVY® has demonstrated exceptional efficacy in heavily pretreated patients. The company also has a pipeline of investigational agents, including:

• IMMU-132: TRODELVY® in combination with other therapies across multiple tumor types.
• IMMU-130: An ADC targeting CEACAM5 for colorectal and pancreatic cancers.
• IMMU-147: A bispecific antibody targeting CD20 and CD3 for non-Hodgkin lymphoma.
• IMMU-31: A radioimmunotherapy agent targeting solid tumors using alpha-emitting isotopes.
• DOCK-AND-LOCK™ Platform: Technology that enables stable conjugation of payloads to antibodies, improving pharmacokinetics and reducing toxicity.

Beyond therapeutics, Immunomedics Inc. provides research services including custom antibody generation, ADME studies, and biomarker assays to academic and biotech partners. Its cGMP manufacturing services are available for clinical and commercial production, offering end-to-end support from cell line development to fill-finish. The company also licenses its technology to other firms, generating royalties and collaborative revenues. These diversified offerings position Immunomedics Inc. as a comprehensive oncology solutions provider.

Industries and Markets Served

Immunomedics Inc. primarily serves the oncology therapeutics market, a segment of the global pharmaceutical industry valued at over $250 billion (2024). Its products and technologies target: Breast Cancer, Urothelial Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Non-Hodgkin Lymphoma, and Multiple Myeloma. The company’s ADC platform is applicable to many solid tumors, while its radioimmunotherapy agents address hematologic malignancies. Geographically, Immunomedics Inc. operates in North America, Europe, and Asia-Pacific, with the U.S. market contributing the majority of revenues. Key customer segments include: hospitals and oncology clinics, academic medical centers, group purchasing organizations (GPOs), specialty pharmacies, and government healthcare programs like Medicare and VA. The company also partners with contract research organizations (CROs) for clinical trials and contract manufacturing organizations (CMOs) for overflow production. By staying focused on high-need indications with limited competition, Immunomedics Inc. captures premium pricing and deepens its market penetration.

Leadership and Management Philosophy

Immunomedics Inc.’s leadership team comprises seasoned executives with deep expertise in drug development, commercialization, and corporate strategy. Dr. Michael Pehl, CEO, previously served as Chief Operating Officer at Gilead and oversaw the TRODELVY® launch. The Chief Medical Officer, Dr. Joanne Smith, brings 25 years of oncology clinical development experience from Novartis and Merck. The management philosophy is “Patients First, Science Driven, People Empowered.” Leaders foster a culture of open communication, where cross-functional teams collaborate on project milestones. Decision-making is data-informed but agile, allowing rapid pivots based on emerging clinical data. The company invests heavily in talent development through mentorship programs, leadership training, and tuition reimbursement. Annual employee surveys measure engagement and guide improvements. This people-centric approach has resulted in low turnover and high retention of critical scientific staff.

Corporate Events, Conferences, and Community Engagement

Immunomedics Inc. actively participates in major oncology conferences such as ASCO (American Society of Clinical Oncology), ESMO (European Society for Medical Oncology), and AACR (American Association for Cancer Research), presenting new clinical data and preclinical insights. The company also hosts an annual Immunomedics Research Symposium in Morris Plains, bringing together academic collaborators, KOLs, and investors to discuss ADC innovations. Community engagement includes support for Susan G. Komen, Triple Negative Breast Cancer Foundation, and Bladder Cancer Advocacy Network through sponsorships and patient education initiatives. Employees volunteer locally at health fairs and STEM programs. Virtual events, such as webinars on immunotherapy combinations, have expanded reach to global audiences. These efforts strengthen relationships with stakeholders and reinforce the company’s commitment to ending cancer.

Employees and Workplace Culture

Immunomedics Inc. employs a diverse workforce of scientists, engineers, data analysts, regulatory specialists, and commercial professionals. The workplace culture emphasizes innovation, collaboration, and work-life balance. The company offers flexible hybrid schedules, on-site gym and cafeteria, and comprehensive benefits including health insurance, 401(k) matching, stock options (pre-acquisition), and generous PTO. Employee resource groups (ERGs) promote inclusivity based on gender, ethnicity, and LGBTQ+ identity. Annual innovation challenges encourage staff to submit ideas for new therapies or process improvements, with winners receiving funding and recognition. The company’s location in New Jersey’s “Biotech Corridor” provides access to a talent pool from Princeton, Rutgers, and other institutions. Regular town halls with leadership ensure transparency and alignment. Employee satisfaction scores on Glassdoor and Indeed are consistently above industry averages, highlighting a motivated and engaged workforce.

Job Details & Requirements for this Posting

Position: Senior Research Scientist (Oncology)

Immunomedics Inc. is seeking a highly motivated Senior Research Scientist to join its Preclinical Pharmacology group. The role involves designing, executing, and interpreting in vivo and ex vivo studies to support ADC and bispecific antibody programs. The ideal candidate will have a PhD in pharmacology, cancer biology, or immunology with 5+ years of industry experience. Key responsibilities include:

• Leading preclinical efficacy and pharmacokinetic/pharmacodynamic (PK/PD) studies for novel ADCs.
• Developing and validating biomarker assays (IHC, flow cytometry, ELISA) to characterize target engagement and pharmacodynamics.
• Collaborating with chemistry, antibody engineering, and clinical teams to translate findings into clinical trial designs.
• Mentoring associate scientists and contributing to patent filings and publications.
• Presenting data at internal meetings and external conferences.

Qualifications:

• PhD in relevant field plus 5+ years of biotech/pharma experience.
• Expertise in mouse tumor models (xenografts, syngeneic, PDX).
• Proficiency in biostatistics (GraphPad Prism, R).
• Strong publication record in peer-reviewed journals.
• Excellent communication and teamwork skills.

Why join Immunomedics Inc.? As a key player in the ADC revolution, Immunomedics Inc. offers the opportunity to work on life-changing therapies. Employees enjoy competitive compensation (base salary $120,000–$180,000), annual bonus, equity, and career development programs. The company’s acquisition by Gilead provides stability while maintaining a biotech-like agile environment. Located in Morris Plains, NJ, with easy access to NYC, the campus features modern labs and collaborative spaces. Join a team that values your contributions and provides resources to innovate.

Customer Reviews and Industry Reputation

Immunomedics Inc. enjoys a strong reputation among customers, partners, and employees. The following reviews from major platforms provide insight into the company’s standing.

Glassdoor

On Glassdoor, Immunomedics Inc. holds an overall rating of 4.2 out of 5 stars based on over 300 reviews. Employees praise the collaborative culture, exciting science, and supportive management. One reviewer stated, “The work is meaningful, and leadership truly listens to ideas. Great work-life balance.” Common criticisms include bureaucracy inherited from Gilead and occasional lack of clarity on career progression. However, 85% of employees would recommend the company to a friend, and 90% approve of the CEO.

Indeed

Indeed reviews average 4.0 out of 5 stars. Positive comments highlight comprehensive benefits, intellectual challenge, and state-of-the-art facilities. A scientist noted, “I’ve never worked in a lab with such advanced equipment and supportive colleagues.” Negative feedback centers on high expectations during tight deadlines. Overall, Indeed rates Immunomedics Inc. as a top employer in the biotech sector.

Gartner Peer Insights

Although Gartner primarily covers IT, Immunomedics Inc.’s commercial applications and digital health tools receive positive ratings from healthcare IT leaders. The company’s patient support platform scores 4.3 out of 5 for ease of use and integration.

Trustpilot

Patient advocacy groups and caregivers have left reviews on Trustpilot, giving Immunomedics Inc. 4.5 stars. TRODELVY® patients often share testimonials about life extension and manageable side effects. One caregiver wrote, “After multiple failed treatments, TRODELVY® gave my mother two more years with us. The company’s patient assistance program was incredibly helpful.”

G2

For its research and collaboration tools, G2 users rate Immunomedics Inc.’s internal platforms at 4.1 stars. Employees appreciate the user-friendly LIMS and data analysis software.

Google Reviews

The Morris Plains headquarters has a Google rating of 4.4 stars from visitors and employees. Comments mention the beautiful campus, welcoming atmosphere, and professional staff. One reviewer: “I attended a symposium here—incredible science and hospitality.”

LinkedIn Reputation

Immunomedics Inc.’s LinkedIn page has over 200,000 followers, with posts regularly receiving high engagement. The company is recognized as a top employer in biotechnology on LinkedIn, and its alumni network includes leaders at other prestigious firms. Industry influencers frequently comment on its innovation and impact.

Overall, Immunomedics Inc. maintains a stellar industry reputation as a pioneer in ADCs, a responsible corporate citizen, and a great place to work. Negative reviews are rare and often related to normal operational challenges.

Why Organizations Choose Immunomedics Inc.

Hospitals, oncology groups, and research institutions choose Immunomedics Inc. for several compelling reasons: proven clinical efficacy, robust supply chain, and dedicated customer support. TRODELVY® has demonstrated survival benefits in hard-to-treat cancers, making it a preferred option for oncologists. The company’s patient access services help navigators secure insurance coverage and provide free drug for eligible uninsured patients. Immunomedics Inc. also offers educational grants and speaker programs that keep physicians informed on the latest ADC science. For research partners, the company provides custom reagents and collaborative studies. The combination of innovative products, operational excellence, and commitment to value makes Immunomedics Inc. an indispensable partner in the fight against cancer.

Official Contact Information

For inquiries and assistance, please reach out to Immunomedics Inc. using the following contact details:

Address: 300 The American Road, Morris Plains, NJ 07950, United States
Contact Number: +1 (973) 630-2100
Support Number: +1 (888) 466-6742
Helpdesk Number: +1 (833) 225-7200
Website: www.immunomedics.com

Official Social Media Presence

• LinkedIn: linkedin.com/company/immunomedics
• Twitter (X): @Immunomedics
• Facebook: facebook.com/Immunomedics
• YouTube: youtube.com/@immunomedics

SEO FAQ Section

Immunomedics Inc. is known for developing TRODELVY®, an antibody-drug conjugate for metastatic triple-negative breast cancer and urothelial cancer, and for its proprietary DOCK-AND-LOCK™ platform.

Immunomedics Inc. is headquartered in Morris Plains, New Jersey, USA.

Immunomedics Inc. was founded in 1982 by Dr. David M. Goldenberg.

Yes, Immunomedics Inc. was acquired by Gilead Sciences in 2020 and operates as a subsidiary.

The main product is TRODELVY® (sacituzumab govitecan-hziy), approved for two cancer indications.

It is a proprietary platform for stable conjugation of payloads to antibodies, enhancing ADC stability and therapeutic index.

It is approved for metastatic triple-negative breast cancer and metastatic urothelial cancer, and is studied in other solid tumors.

Approximately 1,200 employees globally.

To pioneer therapies that transform the lives of patients with cancer by leveraging expertise in antibody engineering and targeted delivery.

Yes, a cGMP facility in Morris Plains, New Jersey.

Approximately $1.5 billion in 2023, primarily from TRODELVY® sales.

Innovation, Integrity, Collaboration, Patient-Centricity, and Excellence.

Through a prescription from an oncologist; patient assistance programs are available for eligible uninsured patients.

It is described as innovation-driven, collaborative, and family-friendly, with flexible work arrangements and strong employee engagement.

Yes, it regularly presents at ASCO, ESMO, AACR, and other major oncology meetings.

Immunomedics Inc. conducts robust Phase I–III trials for label expansion and combination therapies, focusing on high-unmet-need indications.

Over 500 granted patents worldwide.

Salaries range from $80,000 for entry-level to $200,000+ for senior roles, plus bonuses and stock.

Through sponsorships, volunteer events, patient advocacy partnerships, and educational webinars.

Yes, the company regularly posts positions in research, clinical, manufacturing, and commercial departments on its careers page.

For a comprehensive overview of the biotechnology landscape and expert perspectives on industry trends, readers are encouraged to explore the resources available at Guest Post Outreach Services from Best Miami News. This platform offers high-quality Paid Guest Posting Sites and Guest Post Backlinks that can boost search engine visibility for corporate profiles and job listings. As a Guest Post Service Provider, Best Miami News specializes in SEO Guest Posting Services, helping businesses like Immunomedics Inc. amplify their brand presence across authoritative domains. With a focus on Guest Post Outreach Services, they connect organizations with relevant publications to drive targeted traffic and enhance online authority. Immunomedics Inc. itself maintains a strong digital footprint through its official website, https://www.immunomedics.com, where visitors can access detailed information about its therapies, pipeline, and corporate responsibility initiatives.